GB0724556D0 - LAtency associated protein construct with aggrecanase sensitive cleavage site - Google Patents

LAtency associated protein construct with aggrecanase sensitive cleavage site

Info

Publication number
GB0724556D0
GB0724556D0 GBGB0724556.6A GB0724556A GB0724556D0 GB 0724556 D0 GB0724556 D0 GB 0724556D0 GB 0724556 A GB0724556 A GB 0724556A GB 0724556 D0 GB0724556 D0 GB 0724556D0
Authority
GB
United Kingdom
Prior art keywords
aggrecanase
cleavage site
associated protein
latency associated
protein construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0724556.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Priority to GBGB0724556.6A priority Critical patent/GB0724556D0/en
Publication of GB0724556D0 publication Critical patent/GB0724556D0/en
Priority to DK08863207.0T priority patent/DK2262540T3/en
Priority to US12/808,383 priority patent/US8357515B2/en
Priority to ES08863207.0T priority patent/ES2552018T3/es
Priority to EP08863207.0A priority patent/EP2262540B1/en
Priority to PCT/GB2008/004167 priority patent/WO2009077755A2/en
Priority to JP2010538889A priority patent/JP5683272B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
GBGB0724556.6A 2007-12-17 2007-12-17 LAtency associated protein construct with aggrecanase sensitive cleavage site Ceased GB0724556D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0724556.6A GB0724556D0 (en) 2007-12-17 2007-12-17 LAtency associated protein construct with aggrecanase sensitive cleavage site
DK08863207.0T DK2262540T3 (en) 2007-12-17 2008-12-17 Latency proteinkonstrukt with aggrecanasefølsomt cleavage site
US12/808,383 US8357515B2 (en) 2007-12-17 2008-12-17 Latency associated protein construct with aggrecanase sensitive cleavage site
ES08863207.0T ES2552018T3 (es) 2007-12-17 2008-12-17 Construcción de una proteína asociada a la latencia que contenga un sitio de escisión sensible a la agrecanasa
EP08863207.0A EP2262540B1 (en) 2007-12-17 2008-12-17 Latency associated protein construct with aggrecanase sensitive cleavage site
PCT/GB2008/004167 WO2009077755A2 (en) 2007-12-17 2008-12-17 Latency associated protein construct with aggrecanase sensitive cleavage site
JP2010538889A JP5683272B2 (ja) 2007-12-17 2008-12-17 アグリカナーゼ感受性切断部位を有する潜在関連タンパク質構築物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0724556.6A GB0724556D0 (en) 2007-12-17 2007-12-17 LAtency associated protein construct with aggrecanase sensitive cleavage site

Publications (1)

Publication Number Publication Date
GB0724556D0 true GB0724556D0 (en) 2008-01-30

Family

ID=39048208

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0724556.6A Ceased GB0724556D0 (en) 2007-12-17 2007-12-17 LAtency associated protein construct with aggrecanase sensitive cleavage site

Country Status (7)

Country Link
US (1) US8357515B2 (enExample)
EP (1) EP2262540B1 (enExample)
JP (1) JP5683272B2 (enExample)
DK (1) DK2262540T3 (enExample)
ES (1) ES2552018T3 (enExample)
GB (1) GB0724556D0 (enExample)
WO (1) WO2009077755A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895420B2 (en) 2013-06-05 2018-02-20 B.G. Negev Technologies And Applications Ltd., At Ben Gurion University IL-1beta propeptide and IL-1Ra chimera and methods of using the same
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
ES2780274A1 (es) 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103002A (en) 1977-02-08 1978-07-25 Board Of Regents, University Of Florida Bioglass coated A1203 ceramics
US4234972A (en) 1978-06-21 1980-11-25 Board Of Regents, State Of Florida Bioglass coated metal substrate
US4725234A (en) 1985-08-15 1988-02-16 Ethridge Edwin C Alveolar bone grafting process with controlled surface active ceramics
DE3907663A1 (de) 1989-03-09 1990-09-13 Espe Stiftung Knochenersatzteil aus glasionomerzement
FR2651439B1 (fr) 1989-09-06 1994-09-23 Fbfc International Sa Nv Materiau bioreactif pour prothese ou implants composites.
US5074916A (en) 1990-05-18 1991-12-24 Geltech, Inc. Alkali-free bioactive sol-gel compositions
JP2807752B2 (ja) 1993-05-17 1998-10-08 ティーディーケイ株式会社 結晶化ガラス材
GB9319971D0 (en) 1993-09-28 1993-11-17 Cookson Group Plc Cobalt glass compositions for coatings
US5679338A (en) * 1994-05-12 1997-10-21 Osteoarthritis Science, Inc. Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues
FI101129B (sv) 1995-01-13 1998-04-30 Vivoxid Oy Nya bioaktiva glas och deras användning
US6224913B1 (en) 1996-05-09 2001-05-01 The Trustees Of The University Of Pennsylvania Conditioning of bioactive glass surfaces in protein containing solutions
FR2749759B1 (fr) 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
AU4723297A (en) 1996-10-23 1998-05-15 Sunstar Inc. Oral preparations containing biologically active crystallized glass
DE69806714T2 (de) 1997-03-13 2003-04-03 Saint-Gobain Glass France, Courbevoie Kalknatron-silikatglaszusammensetzungen und deren anwendungen
US6482444B1 (en) 1999-06-14 2002-11-19 Imperial College Innovations Silver-containing, sol/gel derived bioglass compositions
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
DE10111449A1 (de) 2001-03-09 2002-09-26 Schott Glas Verwendung von bioaktivem Glas in Zahnfüllmaterial
US20060233887A1 (en) 2003-02-14 2006-10-19 The North West London Hospitals N H S Trust Bioactive material for use in stimulating vascularization
DE112004000094A5 (de) 2003-02-25 2008-04-03 Schott Ag Antimikrobiell wirkendes Borosilicatglas
US6905723B2 (en) 2003-05-30 2005-06-14 Depuy Products, Inc. Strontium-substituted apatite coating
CN1292804C (zh) 2004-03-08 2007-01-03 西安交通大学 含锶纳米磷酸钙生物活性骨水泥的制备工艺
DE102004026432A1 (de) 2004-05-29 2005-12-22 Schott Ag Glaszusammensetzungen als antimikrobieller Zusatz für Dentalmaterialien und deren Verwendung
BRPI0517815B1 (pt) 2004-11-12 2016-08-23 Dentsply Detrey Gmbh composição vítrea de aluminossilicato, seu uso, carga vítrea em partículas, composição de cimento dentário de ionômero de vidro e processo para sua preparação
WO2007020613A1 (en) 2005-08-12 2007-02-22 University Of Limerick A synthetic graft having a glass network
DE102006036019A1 (de) 2006-08-02 2008-02-07 Pemeas Gmbh Membran-Elektroden-Einheit und Brennstoffzellen mit erhöhter Leistung
US20080182920A1 (en) 2007-01-26 2008-07-31 Mark Robert Towler Bone cement

Also Published As

Publication number Publication date
ES2552018T3 (es) 2015-11-25
JP5683272B2 (ja) 2015-03-11
US8357515B2 (en) 2013-01-22
JP2011507498A (ja) 2011-03-10
US20100310515A1 (en) 2010-12-09
EP2262540A2 (en) 2010-12-22
WO2009077755A2 (en) 2009-06-25
WO2009077755A3 (en) 2009-10-15
DK2262540T3 (en) 2015-10-19
EP2262540B1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
EP2134446A4 (en) BIOGAS PROCESSING
FI20065391L (fi) Anturointijärjestely
DK2215110T3 (da) Alfa-amylasevarianter med ændrede egenskaber
DK3118220T3 (da) Protein
DK3354267T3 (da) Stabiliseret sulforaphan
DK1849352T3 (da) Mejetærsker
DK2035369T3 (da) Terapeutiske
BRPI0814971A2 (pt) Proteína
BRPI0812916A2 (pt) Chupeta
DE112008001742A5 (de) Sensoranordnung
EP2039418A4 (en) Mixing apparatus
BRPI0818598A2 (pt) agentes terapêuticos - 802
DE112008000345A5 (de) Sensoranordnung
DE602007003905D1 (de) Verbinder
DK2118388T3 (da) Byggeenhed
DK2164318T3 (da) Integreret ensilagesensor
DE112007003333A5 (de) Fermenter
GB0724556D0 (en) LAtency associated protein construct with aggrecanase sensitive cleavage site
EP2158641A4 (en) Connector
DE602007001119D1 (de) Verbinder
ATE410929T1 (de) Verbessertes getränk
ATE519980T1 (de) Verbinder
DE602007001118D1 (de) Verbinder
PL1999281T3 (pl) Ulepszona pionowa
DE112007000996A5 (de) Sensor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)